Last reviewed · How we verify
CD5-targeted CAR-T cells
At a glance
| Generic name | CD5-targeted CAR-T cells |
|---|---|
| Sponsor | Peking University People's Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies (PHASE1)
- Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL (PHASE1, PHASE2)
- Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (PHASE1, PHASE2)
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma (EARLY_PHASE1)
- Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD5-targeted CAR-T cells CI brief — competitive landscape report
- CD5-targeted CAR-T cells updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI